The Debut of Inflammatory Musculoskeletal Pathology in Patients Receiving Anticancer Therapy with PD-1/PD-L1 Pathway Inhibitors
Objective: to describe musculoskeletal immune-mediated adverse events (iAEs) associated with the therapy of solid tumors with immune checkpoint inhibitors (ICIs, inhibitors of the PD-1/PD-L1 pathway).Patients and methods. 13 patients receiving ICIs therapy with musculoskeletal iAEs were examined. Th...
Saved in:
| Main Authors: | A. D. Koltakova, A. M. Lila, O. G. Alekseeva, A. A. Fedenko, Y. V. Gridneva, A. S. Olshanskaya |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2022-10-01
|
| Series: | Современная ревматология |
| Subjects: | |
| Online Access: | https://mrj.ima-press.net/mrj/article/view/1347 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Rheumatic aspects of arthralgias associated with aromatase inhibitor therapy (analysis of a clinical case series)
by: A. D. Koltakova, et al.
Published: (2023-02-01) -
Safety and toxicity risks of radiotherapy combined with PD-1/PD-L1 inhibitors: A comprehensive review
by: Lijing Zeng, et al.
Published: (2025-07-01) -
Reprogramming the immunosuppressive tumor microenvironment results in successful clearance of tumors resistant to radiation therapy and anti-PD-1/PD-L1
by: Debayan Mukherjee, et al.
Published: (2023-12-01) -
Anti-PD-1 Autoantibody Predicts Survival of Patients With Hepatocellular Carcinoma Receiving Atezolizumab/Bevacizumab
by: Yuki Sasaki, et al.
Published: (2024-01-01) -
The administration of PD-1 and PD-L1 inhibitors in pediatric hematology: a literature review
by: Aleksandra S. Paderina, et al.
Published: (2024-07-01)